IN187337B - - Google Patents

Info

Publication number
IN187337B
IN187337B IN507CA1997A IN187337B IN 187337 B IN187337 B IN 187337B IN 507CA1997 A IN507CA1997 A IN 507CA1997A IN 187337 B IN187337 B IN 187337B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Deborah Marie Sherman
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN187337(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of IN187337B publication Critical patent/IN187337B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN507CA1997 1996-03-25 1997-03-21 IN187337B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
IN187337B true IN187337B (cg-RX-API-DMAC7.html) 2002-03-30

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
IN507CA1997 IN187337B (cg-RX-API-DMAC7.html) 1996-03-25 1997-03-21

Country Status (34)

Country Link
EP (2) EP2881110A1 (cg-RX-API-DMAC7.html)
JP (2) JP4771565B2 (cg-RX-API-DMAC7.html)
KR (1) KR101096512B1 (cg-RX-API-DMAC7.html)
CN (2) CN1090018C (cg-RX-API-DMAC7.html)
AR (1) AR006519A1 (cg-RX-API-DMAC7.html)
AT (1) ATE257011T1 (cg-RX-API-DMAC7.html)
AU (1) AU727653B2 (cg-RX-API-DMAC7.html)
BR (1) BR9701304A (cg-RX-API-DMAC7.html)
CA (1) CA2199778C (cg-RX-API-DMAC7.html)
CO (1) CO4761054A1 (cg-RX-API-DMAC7.html)
CY (1) CY2442B1 (cg-RX-API-DMAC7.html)
CZ (1) CZ291637B6 (cg-RX-API-DMAC7.html)
DE (1) DE69727000T2 (cg-RX-API-DMAC7.html)
DK (1) DK0797991T3 (cg-RX-API-DMAC7.html)
EG (1) EG24198A (cg-RX-API-DMAC7.html)
ES (1) ES2210454T3 (cg-RX-API-DMAC7.html)
HU (1) HU224617B1 (cg-RX-API-DMAC7.html)
IL (1) IL120382A (cg-RX-API-DMAC7.html)
IN (1) IN187337B (cg-RX-API-DMAC7.html)
NO (2) NO320355B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ314442A (cg-RX-API-DMAC7.html)
PA (1) PA8426401A1 (cg-RX-API-DMAC7.html)
PE (1) PE57198A1 (cg-RX-API-DMAC7.html)
PL (2) PL195564B1 (cg-RX-API-DMAC7.html)
PT (1) PT797991E (cg-RX-API-DMAC7.html)
PY (1) PY970019A (cg-RX-API-DMAC7.html)
RU (1) RU2176912C2 (cg-RX-API-DMAC7.html)
SK (1) SK281530B6 (cg-RX-API-DMAC7.html)
SV (1) SV1997000015A (cg-RX-API-DMAC7.html)
TR (1) TR199700190A2 (cg-RX-API-DMAC7.html)
TW (1) TW493993B (cg-RX-API-DMAC7.html)
UA (1) UA44904C2 (cg-RX-API-DMAC7.html)
UY (1) UY24613A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA972403B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
AU2002241764A1 (en) * 2000-10-19 2002-06-18 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003082805A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
WO2004069228A2 (en) * 2003-02-07 2004-08-19 Omega Farma Ehf. Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
IN2003MU00504A (cg-RX-API-DMAC7.html) * 2003-06-05 2005-05-13 Alembic Ltd
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DK1502587T3 (da) 2003-07-30 2007-01-02 Pharmathen Sa Formulering med vedvarende frigivelse af venlafaxinhydrochlorid
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
RU2340331C2 (ru) 2004-02-04 2008-12-10 Алембик Лимитед Форма пролонгированного высвобождения венлафаксина гидрохлорида
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
ITFI20050206A1 (it) * 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
AU2007242077B2 (en) 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺
JP2023127913A (ja) * 2022-03-02 2023-09-14 共和薬品工業株式会社 ベンラファキシン塩酸塩含有顆粒
JP2025120141A (ja) 2024-02-03 2025-08-15 共和薬品工業株式会社 ベンラファキシン塩酸塩含有徐放性顆粒の製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DK0639374T3 (da) * 1993-06-28 2002-05-06 American Home Prod Nye behandlingsmetoder ved anvendelse af phenethylderivater
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
SK30197A3 (en) 1997-10-08
BR9701304A (pt) 1998-09-29
CZ291637B6 (cs) 2003-04-16
KR970064599A (ko) 1997-10-13
CY2442B1 (en) 2004-11-12
PE57198A1 (es) 1998-10-10
PL195564B1 (pl) 2007-10-31
DE69727000D1 (de) 2004-02-05
TR199700190A2 (xx) 1997-10-21
IL120382A (en) 2003-06-24
NO320355B1 (no) 2005-11-28
DE69727000T2 (de) 2004-06-09
JP2008156374A (ja) 2008-07-10
NO971206L (no) 1997-09-26
PY970019A (es) 2006-07-03
CZ77297A3 (en) 1997-11-12
RU2176912C2 (ru) 2001-12-20
UY24613A1 (es) 2000-09-29
HK1056686A1 (en) 2004-02-27
SK281530B6 (sk) 2001-04-09
DK0797991T3 (da) 2004-04-05
PL318954A1 (en) 1997-09-29
PL188444B1 (pl) 2005-02-28
CA2199778A1 (en) 1997-09-25
ATE257011T1 (de) 2004-01-15
CN1090018C (zh) 2002-09-04
UA44904C2 (uk) 2002-03-15
KR101096512B1 (ko) 2014-11-28
AU727653B2 (en) 2000-12-21
IL120382A0 (en) 1997-07-13
HU224617B1 (hu) 2005-11-28
EG24198A (en) 2008-10-14
ZA972403B (en) 1998-09-21
NO971206D0 (no) 1997-03-14
EP2881110A1 (en) 2015-06-10
PT797991E (pt) 2004-05-31
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
SV1997000015A (es) 1997-08-13
EP0797991B1 (en) 2004-01-02
TW493993B (en) 2002-07-11
HU9700589D0 (en) 1997-05-28
JPH107552A (ja) 1998-01-13
AU1640097A (en) 1997-10-02
CA2199778C (en) 2005-12-20
CN1164389A (zh) 1997-11-12
NO20050379L (no) 1997-09-26
HUP9700589A3 (en) 2001-03-28
JP4771565B2 (ja) 2011-09-14
CO4761054A1 (es) 1999-04-27
CN1403077A (zh) 2003-03-19
HUP9700589A2 (en) 1997-09-29
ES2210454T3 (es) 2004-07-01
MX9701873A (es) 1997-09-30
AR006519A1 (es) 1999-09-08
EP0797991A1 (en) 1997-10-01

Similar Documents

Publication Publication Date Title
AR026661A2 (cg-RX-API-DMAC7.html)
BRPI9713914B8 (cg-RX-API-DMAC7.html)
ITMI960427A0 (cg-RX-API-DMAC7.html)
IN191628B (cg-RX-API-DMAC7.html)
IN186313B (cg-RX-API-DMAC7.html)
BR9603859A (cg-RX-API-DMAC7.html)
ITBZ960033A0 (cg-RX-API-DMAC7.html)
BR7601346U (cg-RX-API-DMAC7.html)
ECSDI960346S (cg-RX-API-DMAC7.html)
IN189215B (cg-RX-API-DMAC7.html)
ECSDI960386S (cg-RX-API-DMAC7.html)
ITCN960004V0 (cg-RX-API-DMAC7.html)
IN186767B (cg-RX-API-DMAC7.html)
BR7600721U (cg-RX-API-DMAC7.html)
CN3043413S (cg-RX-API-DMAC7.html)
CN3040024S (cg-RX-API-DMAC7.html)
CN3044168S (cg-RX-API-DMAC7.html)
CN3039696S (cg-RX-API-DMAC7.html)
CN3043073S (cg-RX-API-DMAC7.html)
CN3042289S (cg-RX-API-DMAC7.html)
CN3044170S (cg-RX-API-DMAC7.html)
CN3040621S (cg-RX-API-DMAC7.html)
CN3044169S (cg-RX-API-DMAC7.html)
CN3043414S (cg-RX-API-DMAC7.html)
CN3042589S (cg-RX-API-DMAC7.html)